Side Effects of Chemotherapy and Combined Chemohormonal Therapy in Women With Early-Stage Breast Cancer
Top Cited Papers
Open Access
- 1 December 2001
- journal article
- review article
- Published by Oxford University Press (OUP) in JNCI Monographs
- Vol. 2001 (30) , 135-142
- https://doi.org/10.1093/oxfordjournals.jncimonographs.a003451
Abstract
The decision to receive chemotherapy or chemohormonal therapy involves careful consideration of both the potential benefits and possible risks of therapy. There are substantial short- and long-term side effects from chemotherapy. By convention, short-term side effects include those toxic effects encountered during chemotherapy, while long-term side effects include later complications of treatment arising after the conclusion of adjuvant chemotherapy. These side effects vary, depending on the specific agents used in the adjuvant regimen as well as on the dose used and the duration of treatment. There is also considerable variability in side effect profile across individuals. This review will focus on the short- and long-term toxicity seen with the most commonly used adjuvant chemotherapy and chemohormonal therapy regimens.Keywords
This publication has 73 references indexed in Scilit:
- Fatigue in Breast Cancer Survivors: Occurrence, Correlates, and Impact on Quality of LifeJournal of Clinical Oncology, 2000
- Fatigue in Women Receiving Adjuvant Chemotherapy for Breast CancerJournal of Pain and Symptom Management, 1999
- Is Fatigue a Long-term Side Effect of Breast Cancer Treatment?Cancer Control, 1999
- Polychemotherapy for early breast cancer: an overview of the randomised trialsThe Lancet, 1998
- Characteristics and correlates of fatigue after adjuvant chemotherapy for breast cancer.Journal of Clinical Oncology, 1998
- Quality of life and preferences for treatment following systemic adjuvant therapy for early-stage breast cancer.Journal of Clinical Oncology, 1998
- Side effects of cyclophosphamide, methotrexate, and 5‐fluorouracil (CMF) chemotherapy for breast cancer.Cancer Practice, 1998
- Increased intensification and total dose of cyclophosphamide in a doxorubicin-cyclophosphamide regimen for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-22.Journal of Clinical Oncology, 1997
- Dose and Dose Intensity of Adjuvant Chemotherapy for Stage II, Node-Positive Breast CarcinomaNew England Journal of Medicine, 1994
- Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results from the National Surgical Adjuvant Breast and Bowel Project B-15.Journal of Clinical Oncology, 1990